{'fraction_non_alphanumeric': 0.03561253561253561, 'fraction_numerical': 0.005698005698005698, 'mean_word_length': 5.390909090909091, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interferon in the treatment of cutaneous T‐cell lymphoma

ABSTRACT:  Interferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T‐cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete responses of > 20%. Side‐effects are predictable, generally well tolerated and dose‐related. The efficacy of IFN has increased with combination therapy without any significant increase in attendant side‐effects. An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper.